(Q35213250)

7 August 2017

1 reference

title

Immunologic principles and immunotherapeutic approaches in ovarian cancer (English)

1 reference

7 August 2017

1 reference

1 reference

Keith L Knutson

1

1 reference

7 August 2017

Tyler J Curiel

series ordinal

2

1 reference

7 August 2017

Lupe Salazar

series ordinal

3

1 reference

7 August 2017

Mary L Disis

series ordinal

4

1 reference

7 August 2017

1 August 2003

1 reference

Hematology / Oncology Clinics of North America

7 August 2017

1 reference

7 August 2017

17

1 reference

7 August 2017

4

1 reference

7 August 2017

1051-1073

1 reference

Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

The ErbB signaling network: receptor heterodimerization in development and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Expression of MAGE-1, MAGE-2, MAGE-3/-6 and MAGE-4a/-4b genes in ovarian tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Epithelial mucin genes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

The p53 tumor suppressor gene frequently is altered in gynecologic cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Serum p53 auto-antibodies: incidence in familial breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Circulating antibodies against p53 protein in patients with ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Selection of carbohydrate antigens in human epithelial ovarian cancers as targets for immunotherapy: serous and mucinous tumors exhibit distinctive patterns of expression

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

The role of cytokines in both the normal and malignant ovary

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

CD4+ CD25+ suppressor T cells: more questions than answers

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Serum M3/M21 in ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Primary ovarian cancer cultures are resistant to Fas-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

The central role of CD4(+) T cells in the antitumor immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Active immunization against cancer with dendritic cells: the near future

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Interleukin-12 and Flt3 ligand differentially promote dendropoiesis in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Cytokines regulate proteolysis in major histocompatibility complex class II-dependent antigen presentation by dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Flt3 ligand induces tumor regression and antitumor immune responses in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Human natural killer cells: their origin, receptors and function

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Effects of IL-12 on human ovarian tumors engrafted into SCID mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Innate immunity and autoimmunity: from self-protection to self-destruction

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Therapy with cultured T cells: principles revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Tumor immunology--towards a paradigm of reciprocal research

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Strategies to overcome immune ignorance and tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Dendritic cells as vectors for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

1 reference

7 January 2021

Immunotherapeutic potential of whole tumour cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

The coming of age of tumour immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Clinical trials of Herceptin(trastuzumab).

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Improving the efficacy of antibody-based cancer therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Signaling antibodies in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Antibody-directed, effector cell-mediated tumor destruction

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Overexpression of folate binding protein in ovarian cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: Clinical results in patients with minimal residual disease of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Adoptive T-cell therapy for the treatment of solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2803%2900064-9

7 January 2021

10.1016/S0889-8588(03)00064-9

Identifiers

DOI

1 reference

release_cfjivgh2xzhihpen4b3nlzbftu

7 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cfjivgh2xzhihpen4b3nlzbftu

24 November 2022

mapped directly with Wikidata item

1 reference